In this multinational, phase 3, head-to-head trial (ALPINE), patients who received zanubrutinib — a Bruton’s tyrosine kinase (BTK) inhibitor with greater specificity– rather than the BTK inhibitor ibrutinib, had significantly longer progression-free survival in individuals with relapsed or refractory CLL or SLL, and zanubrutinib was linked to fewer cardiac side events.

The decision to remove Lumoxiti from the US market was attributable to its extremely poor clinical uptake because there were other treatment choices available, according to AstraZeneca’s letter to healthcare professionals. Its limited uptake may also have been caused by the complicated administration, the requirement for toxicity prophylaxis, and the need for safety monitoring. The elimination has nothing to do with the drug’s efficacy or safety.

In this single-group, phase 1-2 trial, sotorasib (LUMAKRAS, Amgen) demonstrated antitumor effect in patients with KRAS p.G12C-mutated advanced pancreatic cancer who had undergone prior therapy and had an acceptable safety profile.

Sunlenca (lenacapavir), which comes in 300 mg tablets and a 463.5 mg/1.5 mL injection, provides doctors with a long-needed twice-yearly option for patients with complicated past treatment histories who would otherwise have few treatment options.

In this phase 3 double-blind, randomized, 72-week controlled trial of 2,539 adults with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight.

A 61-year-old woman taking methotrexate for RA, which has been stable for several years, has new monoclonal protein discovered on routine follow-up. Physical and routine labs are normal. Electrophoresis displays an IgG κ monoclonal protein spike of 0.8 g/dL. What is the proper follow-up?